Smoking habits and progression of coronary and aortic artery calcification: A 5-year follow-up of community-dwelling Japanese men. by PHAM Tai et al.
Smoking habits and progression of coronary and
aortic artery calcification: A 5-year
follow-up of community-dwelling Japanese men.
著者 PHAM Tai, FUJIYOSHI Akira, HISAMATSU Takashi,
KADOWAKI Sayaka, KADOTA Aya, ZAID Maryam,
KUNIMURA Ayako, TORII Sayuki, SEGAWA












Smoking habits and progression of coronary and aortic artery calcification: a 5-year follow-up 
of community-dwelling Japanese men 
 
Author names:   
Tai Pham a,b, Akira Fujiyoshi c,d, Takahashi Hisamatsu c,e, Sayaka Kadowaki c, Aya Kadota a,c, Maryam 
Zaid a, Ayako Kunimura a, Sayuki Torii c, Hiroyoshi Segawa a, Keiko Kondo c, Minoru Horie a,f, 
Katsuyuki Miura a,c, Hirotsugu Ueshima a,c, for the Shiga Epidemiological Study of Subclinical 
Atherosclerosis (SESSA) Research Group 
 
Affiliations:   
a Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Shiga, Japan 
b University of Medicine and Pharmacy at Ho Chi Minh city, Vietnam 
c Department of Public Health, Shiga University of Medical Science, Shiga, Japan 
d Department of Hygiene, School of Medicine, Wakayama Medical University, Wakayama, Japan 
e Department of Environmental Medicine and Public Health, Faculty of Medicine, Shimane 
University, Izumo, Japan 
f Department of Cardiovascular Medicine, Shiga University of Medical Science, , Shiga, Japan 
 
Corresponding author: 
Katsuyuki Miura, MD, PhD 
Department of Public Health, Shiga University of Medical Science 
Seta Tsukinowa-cho, Otsu city, Shiga prefecture 520-2192, Japan 
Tel: +81 (77) 548-2191 
Fax: +81 (77) 543-9732 
E-mail: miura@belle.shiga-med.ac.jp  
2 
 
Types of paper: Original research paper / Clinical and population research paper 
Abstract:  250 words 
Main text:   2686 words 
Total number of tables and figures:  2 tables, 1 figure  









Background and aims: To examine whether smoking habits, including smoking amount and cessation 
duration at baseline, are associated with atherosclerosis progression. 
Methods: At baseline (2006-08, Japan), we obtained smoking status, amount of smoking and time 
since cessation for quitters in a community-based random sample of Japanese men initially aged 40-
79 years and free of cardiovascular disease. Coronary artery calcification (CAC) and aortic artery 
calcification (AAC) as biomarker of atherosclerosis was quantified using Agatston’s method at 
baseline and after 5 years of follow-up. We defined progression of CAC and AAC (yes/no) using 
modified criteria by Berry. 
Results: A total of 781 participants was analyzed. Multivariable adjusted odds ratios (ORs) of CAC 
and AAC progression for current smokers were 1.73 (95% CI, 1.09−2.73) and 2.47 (1.38−4.44), 
respectively, as compared to never smokers. In dose-response analyses, we observed a graded positive 
relationship of smoking amount and CAC progression in current smokers (multivariable adjusted ORs: 
1.23, 1.72, and 2.42 from the lowest to the highest tertile of pack-years). Among the former smokers, 
earlier quitters (≥10.7 years) had similar ORs of the progression of CAC and AAC to that of 
participants who had never smoked. 
Conclusions: Compared with never smokers, current smokers especially those with greater pack-years 
at baseline had higher risk of atherosclerosis progression in community-dwelling Japanese men. 
Importantly, the residual adverse effect appears to be present for at least ten years after smoking 
cessation. The findings highlight the importance of early avoidance or minimizing smoking exposure 
for the prevention of atherosclerotic disease.  
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Cigarette smoking is a major preventable risk factor for cardiovascular diseases (CVD). Recent 
estimates reported that approximately 29.6% of Japanese men smoke, although the rates of smoking 
have declined since 1960s, and this proportion is higher than those of Western populations [1, 2]. The 
adverse effects of smoking continuation relative to smoking cessation on CVD risk have been reported 
[3, 4]. However, it is still unclear how smoking amount and duration of cessation affect the progression 
of atherosclerosis, a process which silently leads to CVD events. This investigation is important for 
consolidating evidence with hard outcomes for emphasizing prevention in earlier stages of CVD.  
Some earlier studies have sought to cross-sectionally evaluate the effect of smoking and smoking 
cessation on prevalence of coronary artery calcification (CAC), a robust measure of coronary 
atherosclerosis [5-11]. In the current study, we aimed to examine whether smoking habits, including 
amount of smoking and duration of cessation (for quitters) at baseline, are associated with progression 




The Shiga Epidemiological Study of Subclinical Atherosclerosis study (SESSA) is a study of 
subclinical atherosclerosis and its determinants on a community-based sample of Japanese residents. 
Details as described previously [12, 13]. In brief, between 2006 and 2008, we randomly selected and 
invited 2379 Japanese men aged 40 to 79 years who were residents of Kusatsu City, Shiga, based on 
the Basic Residents' Register of the city. The Register contains information on name, sex, birth date, 
and address of residents. A total of 1094 men agreed to participate (The participation rate was 46%). 
All the participants provided informed consent and the study has been approved by the Institutional 
Review Board of Shiga University of Medical Science.  
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Data on medical history, use of medications, smoking, and other lifestyle factors were collected from 
each participant using a self-administered questionnaire. Trained technicians confirmed the completed 
questionnaire with participants.  
 
Follow-up 
Participants in the baseline survey were then recruited for a follow-up examination between 2010 and 
2014. A total of 853 participants completed both the baseline and the follow-up diagnostic imaging 
exam [14]. We excluded participants with missing data on AAC score due to incomplete slice coverage 
of the aorta, smoking status at baseline and participants with history of stroke, myocardial infraction, 
or revascularization at baseline. Consequently, 781 men were analyzed.  
 
Ascertainment of smoking habits 
All the variables pertinent to smoking was based on self-report obtained at baseline [13]. Such 
variables include smoking status (never, former, current), cumulative smoking exposure (pack-years 
of smoking) and cessation interval (among former smoker). Current smokers were participants who 
smoked in the last 30 days, whereas former smokers were those with past history of smoking but no 
consumption of cigarettes within the previous 30 days. Participants who had never smoked were 
defined as never smokers. Pack-years are the daily dose (in 20 cigarettes per day) multiplied by the 
duration of smoking (in years). Time since smoking cessation was calculated by subtracting age at 
cessation from age at baseline.  
 
Ascertainment of atherosclerosis 
Atherosclerosis was assessed by radiographic detection of calcific deposits in the coronary artery and 
aortic artery. At the baseline, each participant was scanned once by either electron-beam computed 
tomography (EBCT) using a C-150 scanner (Imatron South San Francisco, CA, USA) or 16-channel 
multi-detector row computed tomography (MDCT) using an Aquilion scanner (Toshiba, Tokyo, Japan). 
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In follow-up, all participants were scanned by 64-channel MDCT. The detailed methodology for 
acquisition and interpretation of the scans has been described [5, 14]. In brief, images of every 3 mm 
level from the level of the root of the aorta through the heart were used for measurement of CAC; and 
every 6 mm level from the aortic arch to the iliac bifurcation were used for measurement of AAC. A 
focus of calcification score was defined as the presence of minimum of three contiguous pixels (area 
= 1 mm2) with density >130 Hounsfield units (HU) using a DICOM workstation and AccuImage 
software (AccuImage Diagnostics, South San Francisco, CA, USA), then CAC and AAC score was 
calculated according to the Agatston method [15].  
Atherosclerosis progression in our study is included development and progression of atherosclerosis. 
We defined CAC progression (yes/no) using modified criteria by Berry [16] as follows: for those with 
CAC = 0 at baseline, defined as CAC ≥10 at follow-up; for those with 0<CAC <100 at baseline, defined 
as annualized change of ≥10 Agatston units at follow-up; for those with CAC ≥100 at baseline, defined 
as annualized percentage change of ≥10% at follow-up. Due to only one time imaging at each exam, 
we used a threshold of CAC ≥10 for those with CAC = 0 at baseline, instead of >0 in the original 
definition of Berry [16, 17]. Although AAC progression was not well defined in previous studies, we 
used a strategy similar to the definition of CAC progression. As AAC is approximately a factor of 10 
times higher than the CAC, we defined AAC progression as follows, for those with AAC = 0 at baseline, 
defined as AAC ≥100 at follow-up; for those with 0< AAC <1000 at baseline, defined as annualized 
change of ≥100 Agatston units at follow-up; for those with AAC ≥1000 at baseline, defined as 
annualized percentage change of ≥10% at follow-up. 
  
Ascertainment of covariates  
A self-administered questionnaire was used to obtain sociodemographic information such as age, sex, 
exercise and alcohol consumption, occupation status, education years and other health histories. The 
average of two blood pressure measurements in the right arm of the seated participant after the 
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participant emptied their bladder for urinalysis and sat quietly for 5 minutes, using an automated 
sphygmomanometer with an appropriately-sized cuff was used. We defined hypertension, as use of 
antihypertensive or systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 
mmHg. Height and weight were measured without shoes. Body mass index (BMI) was defined as 
weight (kg) divided by square of height (m). Serum total cholesterol (TC), triglycerides (TG) and 
plasma glucose from a 12-h fasting blood sample were measured using enzymatic assays, and high-
density lipoprotein cholesterol (HDL-c) was determined using a direct method. Low-density 
lipoprotein cholesterol (LDL-c) was estimated using Friedewald’s formula for participants with TG < 
400 mg/dL: LDL-c (mg/dL) = TC (mg/dL) − HDL-c (mg/dL) − TG (mg/dL)/5 [18]. For those with 
TG≥400mg/dL, we treated their LDL-c as missing. Dyslipidemia was defined as TG ≥150 mg/dL or 
HDL-c <40 mg/dL or use of medication [19]. Hemoglobin A1c (HbA1c) was measured by latex 
agglutination immunoassay according to the Japan Diabetes Society protocol (JDS). Then the value of 
HbA1c was converted from HbA1c (JDS) to HbA1c by the National Glycohemoglobin 
Standardization Program (NGSP) using the following formula: NGSP (%) = 1.02 x JDS (%) + 0.25% 
[20]. Diabetes mellitus was defined as use of medication or fasting plasma glucose ≥126 mg/dL or 
HbA1c (NGSP) ≥6.5%.  
 
Statistical analyses 
Characteristics of the study participants and participants without follow-up were presented as mean ± 
standard deviation (SD) or median (25th, 75th) for continuous variables, and as percentages for 
categorical variables as appropriate. Differences in characteristics were evaluated using 1-way 
ANOVA or Kruskal–Wallis tests for continuous variables; and χ2 or Fisher exact tests for categorical 
variables across categories of smoking status.  
Using binary logistic regression, we first obtained odds ratios (ORs) of progression of CAC and AAC 
according to smoking habits (never, former, current) at baseline. In second analysis, we divided current 
smokers into tertiles according to pack-years of smoking, and former smokers into tertiles according 
8 
 
to duration of cessation. Tertiles were used for pack-years and duration of cessation because of (1) no 
well-established cut-off points for these non-normally distributed measures; and (2) a sufficient sample 
size for each group. We obtained ORs of progression of CAC or that of AAC for each subgroup to 
examine dose-responses in reference to never smokers. We used the following three models: crude, 
age-adjusted and multivariable adjusted model which adjusted for age, dyslipidemia (yes/no), 
hypertension (yes/no), diabetes mellitus (yes/no), body max index, exercise (yes/no), and alcohol 
intake (g/week). All covariates were based on the information at baseline and were available for all 
participants.  Interaction analyses between smoking status and covariates for risk of CAC or AAC 
progression were included (data not shown). We repeated the analyses of CAC progression using 
original definition of Berry [16]. All statistical studies were conducted with the SAS software version 
9.4 (SAS Institute, Cary, North Carolina). A 2-tailed p value of p ≤ 0.05 was considered significant.  
 
RESULTS 
Characteristics of the study participants 
In our study, follow-up rate was 78%. The baseline characteristics of the study population according 
to smoking habits at baseline (n = 781) are displayed in Table 1. The average age was 64 years with 
mean follow-up of 5.0 years. Never smokers comprised 146 (18.7%), former smokers 393 (50.3%), 
and current smokers 242 (31.0%) of the study participants at baseline. Current smokers were younger 
and more likely to be company employees. They consumed more alcohol, had a lower blood pressure 
and high frequency of diabetes mellitus than former and never smokers. Former smokers were older, 
and had high levels of blood pressure, TC, LDL-c. Age, SBP, HDL-c, TG, education years, C-reactive 
protein, number of cigarettes per day, pack-years of smoking, percentage of anti-hypertensive 






Current smoking associated with atherosclerosis progression  
Table 2 shows ORs of CAC and AAC progression according to smoking status at baseline. In 
multivariable analyses controlling for age, and other CVD risk factors, current smoker had 73% higher 
odds of CAC progression and 147% higher odds of AAC progression, compared with never smoker. 
All ORs tended to be attenuated after adjusting for covariates. In dose-response analyses, we observed 
a graded positive relationship of cumulative smoking exposure by pack-years with CAC progression 
(multivariable adjusted ORs: 1.23, 1.72, and 2.42 from the lowest to the highest tertile of pack-years) 
but not with AAC progression (Figure 1, Supplementary Table 1 and 2). There were no interactions 
between smoking and other covariates. 
 
Smoking cessation  
As shown in Table 2, in a multivariable adjusted model, former smokers had higher odds of either 
CAC or AAC progression but the relationships were not statistically significant. Among former 
smokers, recent quitters (<10.7 years) had 133% higher odds of AAC compared with never smoker 
(Figure 1, Supplementary Table 2). Otherwise, former smokers with longer duration of cessation 
(≥10.7 years) did not have higher odds of AAC compared with never smokers. We noted a similar 
pattern of results for CAC progression but the odds for recent quitters were elevated only in crude and 
age-adjusted models (Figure 1, Supplementary Table 1).  
For progression of CAC, we also performed analyses with original definition of Berry, but the results 






Smoking and atherosclerosis progression 
This study is one of the first longitudinal evidences in a general population free of CVD showing a 
dose-dependent relationship between tobacco use and cessation on atherosclerosis progression in 
coronary arteries and the aorta. Our study shows several important findings. First, continued cigarette 
smokers, despite their age, had overall progression of CAC and AAC about 2 times as high as that 
among otherwise similar persons who had never smoked. Moreover, the increase magnitude of effect 
in heavy smoking highlights a biological gradient of smoking in the causal relationship with 
atherosclerosis. Finally, our study adds to prior literature by demonstrating that smoking cessation, 
irrespective of the number of previous pack-years, could reduce the progression of atherosclerosis, but 
a residual effect on AAC appears to be present for at least 10 years after cessation.  
Our results support previous findings from epidemiological studies on the relationship of smoking and 
atherosclerosis [21, 22]. All of those studies examined progression of subclinical atherosclerosis at 
two anatomically distinct sites: CAC, and carotid intima-media thickness, but not AAC. The first 
longitudinal study reporting effect of continued or past smoking on CAC progression was based on a 
Danish trial [22]. Although, these sub-analyses did not consider cessation time of former smokers at 
baseline, the conclusion on the dose-response effects of smoking continuation in long-term smokers 
with regard to subclinical CVD was concordant. Our findings are also in line with a previous cross-
sectional study based on this population [5], and others reporting the significant association of cigarette 
smoking with prevalence of CAC and AAC [6-11].  
In pathophysiological perspective, artery calcification is categorized into two types: atherosclerotic 
and medial artery calcification. The mechanisms by which smoking induces artery calcification were 
reported to be related to atherosclerosis occurring in the intima. Enhanced secretion of inflammatory 
cytokines and elevated lipid content within atherosclerotic lesions leads to osteogenic differentiation 
of vascular smooth muscle cells [23]. CAC and AAC as surrogate markers of atherosclerosis were 
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found to be independent predictors of CVD events and all-cause mortality in individuals with no 
previous history of CVD [24-26]. Moreover, progression of CAC has been reported to be associated 
with future CVD events [27]. To manage lifetime risks of CVD events, sensitive biomarkers 
for stratification and prediction of treatment response are needed. The dose relationship of smoking 
relative to smoking cessation with presence and progression of CAC or AAC demonstrate the potential 
utility of these biomarkers in early detection and management of CVD risk.  
Conversely, smoking cessation has been shown to return levels of inflammatory cytokines to levels 
comparable to those of non-smokers [28], and to reverse all-cause mortality including CVD risk [3, 4]. 
Previous studies on either general or high risk male populations have described the variation from 3 to 
10 years in speed of risk-reduction after cessation [29-33]. Given stratified analyses of quitting time, 
our study results suggest that it takes more than ten years after smoking cessation for an individual’s 
level of sub-clinical atherosclerosis to return to a level comparable to that of never smokers. Even 
though attempting smoking cessation is associated with an early reduction in risk of hard outcome, our 
study emphasizes on long-term maintenance of smoking cessation in order to avoid the residual effects. 
Despite the recent declining trend of cigarette smoking in developed Western nations, smoking rates 
in developing Asian countries still remain high [34]. This might be due to the lack of efforts on public 
awareness on health consequences of cigarette smoking in those countries. Using subclinical outcomes, 
our findings, as well as those from other recent studies on CVD incidence and mortality [3], highlight 
the importance of early and continued smoking cessation. In the present study, the association of 
smoking with CAC and AAC progression attenuated after full adjustment in all models, which suggests 
that other factors such as diabetes mellitus, and alcohol consumption also have strong associations 
with CAC and AAC progression. 
 
Limitations and Strengths 
There are some important limitations in this study. First, the current study was conducted only in men, 
hence the results may not be applicable to women. Second, information of smoking parameters and 
12 
 
adjusting covariates were only based on self-reports at baseline. It should be noted that the association 
in this study was estimated by calculating OR, which are surrogate for relative risk and should not be 
misunderstood as such. We also cannot dismiss the possibility that the relatively small sample size in 
our study is the cause for not finding significant interactions with covariates. Additionally, artery 
calcification at the baseline was assessed by either EBCT or MDCT, while all participants were 
scanned by MDCT in follow-up. The technique differences in image acquisition between EBCT and 
MDCT may lead to interscan variability [35]. Finally, we were unable to examine non-calcified plaque 
in the current study, thus limiting our ability to detect early atherosclerosis [36]. The strengths of our 
study include a randomly-selected sample to minimize bias and well-standardized measurements of 
relevant parameters including CAC, AAC and other laboratory data. 
 
CONCLUSIONS 
Compared to never smokers, current smokers (especially those with greater pack-years at baseline) 
had greater risk of progression of atherosclerosis in a community-based sample of men. Importantly, 
the residual adverse effect on coronary artery and aorta appears to be present for at least ten years after 
smoking cessation. The findings highlight the importance of avoiding or minimizing smoking exposure 
for the prevention of subclinical cardiovascular disease.  
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Table 1. Baseline characteristics of 781 male participants aged 40–79 years (SESSA, Shiga, Japan, 2006–2008 at baseline and 2010–2014 at 
follow-up) 
 
 Baseline characteristic  
Study participants according to smoking status at baseline 
Total (n = 781) Never (n = 146) Former (n = 393) Current (n = 242) P value 
Age, years   63.8 ± 9.5 64.3 ± 9.8 65.4 ± 9.0 60.8 ± 9.5 <0.01 
Body mass index, kg/m2  23.5 ± 2.9 23.8 ± 2.7 23.5 ± 2.9 23.5 ± 3.1 0.49 
Systolic blood pressure, mmHg  135.7 ± 18.4 135.3 ± 17.6 137.5 ± 18.8 133.2 ± 17.9  0.02 
Diastolic blood pressure, mmHg  79.9 ± 11.0 80.0 ± 9.8 80.5 ± 11.6 78.7 ± 10.7 0.15 
Diabetes mellitus, %  18.6 16.4 17.6 21.5 0.33 
Total cholesterol, mg/dL  210.3 ± 32.9 209.3 (33.4) 211.3 ± 31.3 209.2 ± 35.2 0.69 
HDL cholesterol, mg/dL  59.1 ± 17.0 59.9 (15.8) 60.8 ± 17.9 55.8 ± 15.7 <0.01 
LDL cholesterol, mg/dL  126.4 ± 30.9 126.6 (30.5) 126.9 ± 28.7 125.3 ± 34.6 0.81 
Triglycerides, mg/dL  106.0 (77.0, 150.0) 97.0 (69.0, 141.0) 101.0 (74.0, 142.0) 127.5 (86.0,167.0)  <0.01 
Medication for hypertension, %  28.2 26.0 33.8 20.1 <0.01 
Medication for dyslipidemia, %  13.2 17.8 13.5 9.9 0.09 
Alcohol intake, g/week  98.0 (7.0, 258.6) 29.3 (0.0, 151.9) 99.1 (12.5, 256.4) 149.2 (12.3, 322.6) <0.01 
Exercise, %  45.6 45.2 54.7 31.0 <0.01 
Occupation status, %      0.20 
Self-employed, agriculture  13.4 11.6 12.8 15.4  
Company employees  44.4 42.5 41.8 49.8  
Unemployed  32.7 34.3 35.7 27.0  
Others  9.5 11.6 9.7 7.9  
Education years, year  12.8 ± 2.4 13.2 ± 2.4 12.5 ± 2.5  12.5 ± 2.3 0.03 
C-reactive protein, mg/L   0.4 (0.2, 0.9) 0.4 (0.2, 0.6) 0.4 (0.2, 0.9) 0.5 (0.2, 1.0) <0.01 
Number of cigarettes per day  NA NA 20.0 (15.0, 30,0) 20.0 (15.0, 25,0) <0.01 
Pack-years of smoking  NA NA 25.0 (12.0, 42.0) 38.7 (23.7, 50.9) <0.01 
Values are expressed as mean ± standard deviation, median (25th, 75th), or percentage. Body mass index was defined as weight (kg) divided 
by square of height (m). Differences in characteristics were evaluated using the analysis of variance, χ2 test, or Kruskal–Wallis test.   
HDL, high-density lipoprotein ; LDL, low-density lipoprotein ; CAC, coronary artery calcification; AAC, Aorta Artery calcification. Diabetes 
mellitus was defined as either fasting glucose ≥126 mg/dL or HbA1c (NGSP) ≥6.5%, or medication use. 
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Table 2 Odds ratios of having CAC and AAC progression by smoking status at baseline in 781 men aged 40-79 years (SESSA, Shiga, Japan, 







No. of CAC 
progression 
(%) 
Odd ratios of having CAC progression 
(95% CI) No. of AAC 
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(%) 
Odd ratios of having AAC progression 
(95% CI) 
Crude Age adjusted 
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 1.82  
(1.17−2.82) a 
1.73 
 (1.09−2.73) a  
64  
(26.5) 





 (1.38−4.44) b 
 
Multivariable adjusted model was adjusted for age, dyslipidemia (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), body max index, 
exercise (yes/no), and alcohol intake (g/week).  
CAC, coronary artery calcification; AAC, Aorta Artery calcification; CI, confidence interval. 
Progression of coronary artery calcification was defined as follows, for those with CACS = 0 at baseline, defined as CAC ≥10 at follow-up; for 
those with 0< CAC <100 at baseline, defined as annualized change of ≥10 Agatston units at follow-up; for those with CAC ≥100 at baseline, 
defined as annualized percentage change of ≥ 10% at follow-up. 
Progression of aorta calcification was defined as follows, for those with AAC =0 at baseline, defined as AAC ≥100 at follow-up; for those with 
0< AAC <1000 at baseline, defined as annualized change of ≥ 100 Agatston units at follow-up; for those with AAC ≥1000 at baseline, defined as 
annualized percentage change of ≥10% at follow-up. 








No. of CAC 
progression (%) 
Multivariable adjusted odd 
ratios of having CAC 
progression  
(95% CI) 
No. of AAC 
progression (%) 
Multivariable adjusted odd 
ratios of having AAC 
progression  
(95% CI) 
Never 146 49 (33.6)  21 (14.4)  
Former smoker 
Tertiles of smoking cessation intervals 
      
  >24.2 years  131 54 (41.2)  24 (18.3)  
  10.7–24.2 years 131 44 (33.6)  32 (24.4)  
  <10.7 years 131 
59 (45.0) 
 41 (31.3)  
Current Smoker 
Tertiles of cumulative smoking exposure   
      
<28.8 pack-years 80 26 (32.5)  18 (22.5)  
28.8–45.4 pack-years 81 37 (45.7)  22 (27.2)  
>45.4 pack-years 81 44 (54.3)  24 (29.6)  
      
 
 
Figure 1. Odds Ratios of having CAC and AAC progression by Smoking Status at baseline, Cumulative Smoking Exposure by Pack-years and 
Smoking Cessation Intervals in 781 Men Aged 40-79 Years (SESSA, Shiga, Japan, 2006-2008 at baseline and 2010-2014 at follow-up) 
 
CAC, coronary artery calcification; AAC, Aorta Artery calcification; CI, confidence interval. Multivariable model adjusted for age, dyslipidemia 




Supplementary Table 1. Odds ratios of having CAC progression by smoking status at baseline, cumulative smoking exposure by pack-years 
and smoking cessation Intervals 
 
Smoking status at baseline 
No. of 
participant 
No. of CAC 
progression (%) 
Odd ratios (95% CI) 
Crude Age adjusted 
Multivariable 
adjusted 
Never 146 49 (33.6) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
Former smoker  
Tertiles of smoking cessation intervals 
     
  >24.2 years  131 54 (41.2) 1.39 (0.85−2.26) 1.25 (0.76−2.04) 1.26 (0.76−2.10) 
  10.7 – 24.2 years 131 44 (33.6) 1.00 (0.61−1.65) 0.97 (0.59−1.61) 0.87 (0.52−1.47) 
  <10.7 years 131 59 (45.0) 1.62 (1.00−2.64) 1.70 (1.04−2.79) a 1.63 (0.98−2.72) 
Current smoker 
Tertiles of cumulative smoking exposure     
     
<28.8 pack-years  80 26 (32.5) 0.95 (0.53−1.70) 1.18 (0.65−2.14) 1.23 (0.67−2.28) 
 28.8 – 45.4 pack-years  81 37 (45.7) 1.67 (0.96−2.90) 1.96 (1.11−3.45) a 1.72 (0.95−3.13) 
 ≥45.4 pack-years  81 44 (54.3) 2.35 (1.35−4.11) b 2.50 (1.42−4.39) b 2.42 (1.34−4.38) a 
CAC, coronary artery calcification; CI, confidence interval. 
Multivariable model adjusted for age, dyslipidemia (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), body max index, exercise 
(yes/no), and alcohol intake (g/week).  
 




Supplementary Table 2. Odds ratios of having AAC progression by smoking status at baseline, cumulative smoking exposure by pack-years 
and smoking cessation intervals 
 
Smoking status at baseline 
No. of 
participant 
No. of AAC 
progression (%) 
Odd ratios (95% CI) 
Crude Age adjusted 
Multivariable 
adjusted 
Never 147 21 (14.4) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
Former smoker  
Tertiles of smoking cessation intervals 
     
  >24.2 years  122 24 (18.3) 1.34 (0.70−2.53) 1.16 (0.61−2.22) 1.14 (0.58−2.22) 
  10.7 – 24.2 years 133 32 (24.4) 1.92 (1.05−3.54) a 1.88 (1.01−3.51) a 1.60 (0.84−3.03) 
  <10.7 years 132 41 (31.3) 2.71 (1.50−4.90) b 2.98 (1.63−5.46) b 2.33 (1.24−4.38) b 
Current smoker 
Tertiles of cumulative smoking exposure     
     
 <28.8 pack-years  80 18 (22.5) 1.73 (0.86−3.48) 2.42 (1.17−5.00) a 2.51 (1.18−5.32) a 
 28.8 – 45.4 pack-years  81 22 (27.2) 2.22 (1.13−4.35) a 2.93 (1.46−5.87) b 2.45 (1.18−5.06) a 
 ≥45.4 pack-years  81 24 (29.6) 2.51 (1.29−4.87) b 2.80 (1.42−5.52) b 2.55 (1.25−5.20) a 
AAC, Aorta Artery calcification; CI, confidence interval. 
Multivariable model adjusted for age, dyslipidemia (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), body max index, exercise 
(yes/no), and alcohol intake (g/week).  





Supplementary Table 3. Odds ratios of having CAC progression by original definition of Berry by smoking status at baseline, cumulative 
smoking exposure by pack-years and smoking cessation intervals 
 
Smoking status at baseline 
No. of 
participant 
No. of CAC 
progression (%) 
Odd ratios (95% CI) 
Crude Age adjusted 
Multivariable 
adjusted 
Never 146 49 (33.6) 1 (Ref.) 1 (Ref.) 1 (Ref.) 
Former smoker  
Tertiles of smoking cessation intervals 
     
  >24.2 years  131 54 (41.2) 1.21 (0.76−1.95) 1.09 (0.68−1.77) 1.19 (0.69−1.85) 
  10.7 – 24.2 years 131 44 (33.6) 0.81 (0.50−1.31) 0.78 (0.48−1.27) 0.73 (0.44−1.20) 
  <10.7 years 131 59 (45.0) 1.42 (0.88−2.28) 1.47 (0.91−2.38) 1.40 (0.86−2.31) 
Current smoker 
Tertiles of cumulative smoking exposure     
     
<28.8 pack-years  80 26 (32.5) 0.88 (0.51−1.54) 1.07 (0.60−1.89) 1.10 (0.61−1.98) 
 28.8 – 45.4 pack-years  81 37 (45.7) 1.29 (0.75−2.23) 1.48 (0.85−2.59) 1.32 (0.74−2.35) 
 ≥45.4 pack-years  81 44 (54.3) 2.03 (1.17−3.52) b 2.13 (1.22−3.71) b 2.01 (1.13−3.58) a 
CAC, coronary artery calcification; CI, confidence interval. 
Multivariable model adjusted for age, dyslipidemia (yes/no), hypertension (yes/no), diabetes mellitus (yes/no), body max index, exercise 
(yes/no), and alcohol intake (g/week).  
P value a <0.05; b <0.01 
Original definition of Berry: Progression of coronary artery calcification was defined as follows, for those with CACS = 0 at baseline, defined as 
CAC >0 at follow-up; for those with 0< CAC <100 at baseline, defined as annualized change of ≥10 Agatston units at follow-up; for those with 
CAC ≥100 at baseline, defined as annualized percentage change of ≥ 10% at follow-up.
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